Nutlin-3

製品コードS1061

Nutlin-3化学構造

分子量(MW):581.5

Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.

サイズ 価格(税別)  
JPY 30710.00
JPY 18260.00
JPY 28220.00
JPY 61420.00
JPY 161020.00

カスタマーフィードバック(4)

  • Caspase 3/7 activation in UKF-NB-3 or UKF-NB-3rNutlin10 μM cells treated nutlin-3 (10 μM), VCR (10 ng/ml), DOX (20 ng/ml), or CDDP (1000 ng/ml).

    Cell Death Dis 2011 2, e243. Nutlin-3 purchased from Selleck.

     

    p53 activation in A76T p53-mutated UKF-NB-3’RITA(10 uM) IV cells. Cells were treated with RITA (10 uM) or nutlin-3 (10 uM) for 24 h and investigated by western blot for the expression of p53 target genes

    Cell death dis 2012 3, e294. Nutlin-3 purchased from Selleck.

  • Ubiquitination of p53 in vivo by BIRC6 in the presence of Nutlin-3. Cells were treated with Nutlin-3 (20 uM, 24 h) before harvest. Cell lysates were immunoprecipitated with anti-p53 antibody and immunoblotted by anti-ubiquitin antibody.

    Int J Oncol 2014 44, 761-8. Nutlin-3 purchased from Selleck.

    d qPCR evaluation of DKK1 in MSCs exposed to melphalan in combination with increasing concentrations of nutlin-3 for 24 h. Cells were pre-treated with nutlin-3 for 20 min prior to chemotherapy. *Indicates p value<0.05, One-way ANOVA with Holm-Sidak post hoc

    Med Oncol, 2016, 33(10):113. Nutlin-3 purchased from Selleck.

製品安全説明書

Mdm2阻害剤の選択性比較

生物活性

製品説明 Nutlin-3 is a potent and selective Mdm2 (RING finger-dependent ubiquitin protein ligase for itself and p53) antagonist with IC50 of 90 nM in a cell-free assay; stabilizes p73 in p53-deficient cells.
ターゲット
Mdm2 [5]
(Cell-free assay)
180 nM
体外試験

Nutlin-3 potently inhibits the MDM2-p53 interaction, leading to the activation of the p53 pathway. Nutlin-3 treatment induces the expression of MDM2 and p21, and displays potent antiproliferative activity with IC50 of ~1.5 μM, only in cells with wild-type p53 such as HCT116, RKO and SJSA-1, but not in the mutant p53 cell lines SW480 and MDA-MB-435. In SJSA-1 cells, Nutlin-3 treatment at 10 μM for 48 hours significantly induces caspase-dependent cell apoptosis by ~45%. Although Nutlin-3 also inhibits the growth and viability of human skin (1043SK) and mouse embryo (NIH/3T3) with IC50 of 2.2 μM and 1.3 μM, respectively, cells remain viable 1 week post-treatment even at 10 μM of Nutlin-3, in contrast with the SJSA-1 cells with viability lost at 3 μM of Nutlin-3 treatment. [1] Nutlin-3 does not induce the phosphorylation of p53 on key serine residues and reveals no difference in their sequence-specific DNA binding and ability to transactivate p53 target genes compared with phosphorylated p53 induced by the genotoxic drugs doxorubicin and etoposide, demonstrating that phosphorylation of p53 on key serines is dispensable for transcriptional activation and apoptosis. [2] Although binding less efficiently to MDMX than to MDM2, Nutlin-3 can block the MDMX–p53 interaction and induce the p53 pathway in retinoblastoma cells (Weri1) with IC50 of 0.7 μM. [3] Nutlin-3 at 30 μM also disrupts endogenous p73-HDM2 interaction and enhances the stability and proapoptotic activities of p73, leading to the dose-dependent cell growth inhibition and apoptosis induction in cells without wild-type p53. [4]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
MCF7 M2PyVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmTtOeKh|ryP NHy3blk1QMLiaB?= M3nVWoJtd2OtczCyO{1QUENvaX7keYNm\CClZXzsJJBzd2yrZnXyZZRqd25iY3;tdIFz[WKuZTD0c{B1cGG2IH;mJIJie2GuIHzleoVtew>? MWWyOlM2ODV4NR?=
NP69 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWDJR|UxRTNzLk[5xtEzNjV2IN88US=> MlrvNlYzPTJ3N{W=
NP460 NYrC[ZV1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkHKTWM2OD1{Mj64OeKyOS5zODFOwG0> MmP1NlYzPTJ3N{W=
C666-1 NFfvXmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWfJR|UxRTF7Lkm1xtE5Njl|IN88US=> MWeyOlI2OjV5NR?=
C666-1 NH7N[pBE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1;2VVExKML3TR?= MWW0PEBp M1nURWROW09? MoLOd4Vve2m2aYrld{BEPjZ4LUGgZ4VtdHNidH:geIhmKGO7dH;0c5hq[yCnZn\lZ5Qhd2ZiY3nzdIxifGmw M17NblI3OjV{NUe1
C666-1  NYjyZnROTnWwY4Tpc44hSXO|YYm= NV\ScIwzOTBiwsXN NVPLO|JjOjRiaB?= MY\EUXNQ NVjJbmsx[WO2aY\heIV{KHSqZTDwOVMheGG2aIfhfUwhfXC{ZXf1cIF1cW6pIIC1N{wheDJzIHHu[EBO\G1{ MoT2NlYzPTJ3N{W=
C666-1 M1;zfWFxd3C2b4Ppd{BCe3OjeR?= MVixNEDDvU1? NILQRZQ1QC95MjDo NGS3dnBFVVOR NHvod2l{\W6|aYTpfoV{KEN4Nk[tNUBk\WyuczD0c{BkcXOybHH0bY4ucW6mdXPl[EBieG:ydH;zbZM> NX;FXJNIOjZ{NUK1O|U>
A549 NUnHRVg3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUeyOEBp MUHJR|UxRTF5Lk[4JOKyKDRwNUKg{txO MXGyOlEzPTJ|MB?=
A549-NTC MoPJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NE\lN2EzPCCq M4jZXWlEPTB;MUmuOFIhyrFiMT65OkDPxE1? MWKyOlEzPTJ|MB?=
A549-920 M1rkVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnPkNlQhcA>? NGjmeXNKSzVyPUOzMlg2KMLzIESuPFQh|ryP NV;KNZY2OjZzMkWyN|A>
CRL-5908 M1nV[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3\jXlI1KGh? M1i4eWlEPTB;M{iuO|EhyrFiMj60N{DPxE1? MUmyOlEzPTJ|MB?=
L6 NI[yWVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWn0XZRSOTEEoN88UeKh NIi0boUzPC92OD:3NkBp MYTEUXNQ NWD5T3hZcW6qaXLpeJMh[2WubIOgdJJwdGmoZYLheIlwdiCjbnSg[Iln\mW{ZX70bYF1cW:w MkLBNlU5PzF5OUS=
C2C12 NF22UVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYOzNWJJOTEEoN88UeKh MojwNlQwPDhxN{KgbC=> MX7EUXNQ MmXTbY5pcWKrdIOgZ4VtdHNicILvcIln\XKjdHnvckBidmRiZHnm[oVz\W62aXH0bY9v M{jkSlI2QDdzN{m0
MCF-7  MkHXSpVv[3Srb36gRZN{[Xl? MmOzNVDDqM7:TR?= M2DidGROW09? MWXpcohq[mm2czDjfYNtcW5iREGgZY5lKESrY3XyxsA> MXKyOVcxOjdyMx?=
DU4475  MnXOSpVv[3Srb36gRZN{[Xl? MlTBOU8yOC9{MDFOwG0> MUeyOOKhcA>? NITLfGVld3ewcnXneYxifGW|IGTvZ4EuOSCmb4PlJIRmeGWwZHXueIx6 Mk\4NlU2PDdzN{S=
SMMC-7721 NHTUW4FHfW6ldHnvckBCe3OjeR?= M3nvRVExKM7:TR?= MmLNOFghcA>? NILkfndFVVOR M{nHfoNifXOnczDEUmEhTFOEIHThcYFo\Q>? NV;JUllSOjV3NESzOlE>
SMMC-7721 MYnGeY5kfGmxbjDBd5NigQ>? MVKxNEDPxE1? M2m3[VQ5KGh? NX7BZ4c{TE2VTx?= NVLJVW9ZcW6mdXPld{B1cGViY3jyc41ifGmwLXLveY5lKHC{b4TlbY4hUU[LMU[geI8heGG{dHnhcIx6KGyxY3HsbZpmKGmwIITo[UBkgXSxcHzhd43DqA>? NEnpV2szPTV2NEO2NS=>
SMMC-7721 M1vqemZ2dmO2aX;uJGF{e2G7 NH\hOFgyOCEQvF2= NEPXSo81QCCq MWLEUXNQ MV3pcoNz\WG|ZYOgeIhmKGW6cILld5Nqd25ibHX2[Ywhd2cEoFnGUmIyyqCvUl7B MWeyOVU1PDN4MR?=
SMMC-7721 M4PnUGZ2dmO2aX;uJGF{e2G7 MVqxNEDPxE1? M3XqelM3KGh? NEXQNFVFVVOR MWDjZZV{\XNidHjlJIVkfG:yaXOg[ZhxemW|c3nvckBw\iCLRlmxOi=> NWnyT3gyOjV3NESzOlE>
MCF-7 MUPGeY5kfGmxbjDBd5NigQ>? Mm\QNVDDqM7:TR?= M3XRRlAuOjRiaB?= M2DV[4lv\HWlZYOgdFU{KGGwZDDwNlEwS2myMR?= Ml72NlU1QDJ|N{O=
OVCAR10 NVjLO|hmTnWwY4Tpc44hSXO|YYm= NHj0Z4oyOMLizszN MkPTNlFpyqB? NEPydJZFVVOR M2WzRYlv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> NVrWWYlwOjV2Mk[1OFg>
NCI-H23 NUDQR4x3TnWwY4Tpc44hSXO|YYm= Mnf4NVDDqM7:TR?= MX6yNYjDqA>? MXzEUXNQ MVLpcoNz\WG|ZYOgdFU{KHC{b4TlbY4hdGW4ZXzz NX\PW2hoOjV2Mk[1OFg>
A2780 M1X0VWZ2dmO2aX;uJGF{e2G7 M1\sc|ExyqEQvF2= NFexU|QzOWkEoB?= MYnEUXNQ M3\GZ4lv[3KnYYPld{BxPTNicILveIVqdiCuZY\lcJM> M2rMPVI2PDJ4NUS4
NCI-H23 MUXGeY5kfGmxbjDBd5NigQ>? M1rvW|ExyqEQvF2= M1rnO|IycMLi MWTEUXNQ MXHk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= MWmyOVQzPjV2OB?=
A2780 MV\GeY5kfGmxbjDBd5NigQ>? NFHH[HgyOMLizszN NIDrXVIzOWkEoB?= NIe5[phFVVOR MXjk[YNz\WG|ZYOgeIhmKE[xeF2xJIxmfmWucx?= NYL5fmRGOjV2Mk[1OFg>
HCT116  NV3HOIhzTnWwY4Tpc44hSXO|YYm= MX[xNEDDvU1? MWmyOEBp MlLmZ4F2e2W|IHGgdFU{NWSncHXu[IVvfCC2ZYTyZZBtd2mmIFexMYFzemW|dDDpckBlcXCub3nkJGhEXDFzNjDjcI9v\XNiREOgZY5lKER6 Mlj4NlU{QDByNUW=
MCF-10CA1a MUTGeY5kfGmxbjDBd5NigQ>? NXLJWXNROTEEoN88US=> MUK0PEBp NVfUVVh[TE2VTx?= MlPIbY5pcWKrdIOgZoF{[WxiaX72ZZNqd25iYX7kJJJm\HWlZXSgWGdHNc7{Mz3pcoR2[2WmIHnueoF{cW:wIITvJIJie2GuIHzleoVtew>? NUXUbGtZOjV{NUe3Nlk>
MCF-10A1  MoSxSpVv[3Srb36gRZN{[Xl? NHfHN3MyOMLizszN Ml3jNlQwPDhiaB?= NH[5ZYhFVVOR NUjpT4VbcW6qaXLpeJMhdWmpcnH0bY9vKG:oIH7vdo1idCCkcnXhd5Qh\XCrdHjlcIlidMLi MV[yOVI2Pzd{OR?=
MCF-10CA1a MmjWSpVv[3Srb36gRZN{[Xl? MVmxNOKh|ryP NI\3W2MzPCCq NY\pPWZMTE2VTx?= NVO0OmZS\GWlcnXhd4V{KHSqZTDUS2Yu|rJ|LXnu[JVk\WRibWLORUBt\X[nbIOgc4ZOVVB{LNMgUW1RQSxiYX7kxsBqdnSnZ4LpcuKh|rMEoEO= M4TRNVI2OjV5N{K5
MCF-10CA1a MYXGeY5kfGmxbjDBd5NigQ>? NFjxbo4yOMLizszN NWDmWoVzOjRiaB?= M3;6[mROW09? MmHJbY5pcWKrdIOgJHRITi4QskOtbY5lfWOnZDDFVGhDOsLibWLORUBidmRicILveIVqdiCneIDy[ZN{cW:w M1viRlI2OjV5N{K5
SK-BR-7 NUOycJRYTnWwY4Tpc44hSXO|YYm= NF60SmkyOMLizszN MmTBNlQhcA>? NV;hSIs1TE2VTx?= MUfpcohq[mm2czCgWGdHNc7{Mz3pcoR2[2WmIFXQTGIzyqCvUl7BJIFv\CCycn;0[YlvKGW6cILld5Nqd25? NELOb|czPTJ3N{eyPS=>
SUM102PT MXfGeY5kfGmxbjDBd5NigQ>? MV2xNOKh|ryP NXvvPVJYOjRiaB?= NXPKXYJMTE2VTx?= NYOzb4FwcW6qaXLpeJMhKFSJRj5OtlMucW6mdXPl[EBGWEiEMtMgcXJPSSCjbnSgdJJwfGWrbjDlfJBz\XO|aX;u NHf4SVIzPTJ3N{eyPS=>
RAW 264.7 NUTrUXNSTnWwY4Tpc44hSXO|YYm= NIPsXmQyOMLizszN NXm4N3FbOzBibXnu M{PB[pBz\X[nboTzJJRp\SCyNUOgdoVlfWO2aX;uJIlvKHKnc4DvcpNmKHSxIFzQVy=> MV[yOVE4OjV2Nx?=
RAW 264.7 M4\y[WZ2dmO2aX;uJGF{e2G7 MUSxNOKh|ryP NGrSWJQ{OCCvaX6= M2jzNpJm\HWlZYOgeIhmKEySUz3heYdu\W62ZXSgeIhmKE6ILd86RkBtfWOrZnXyZZNmKHKncH;yeIVzKGenbnWgZYN1cX[rdIm= MlnaNlUyPzJ3NEe=
RAW 264.7 NVLMc2w3TnWwY4Tpc44hSXO|YYm= M37PfFExyqEQvF2= MX[zNEBucW5? NFi3e2RqdmirYnn0d{BNWFNvaX7keYNm\CCQTzDwdo9lfWO2aX;uxsA> NYryTItnOjVzN{K1OFc>
MCF7  NWjH[pRsS2WubDDWbYFjcWyrdImgRZN{[Xl? MorQNk42KML3TR?= MWG1JIQ> M1TaS2ROW09? NHu5VFl{\W6|aYTpfoV{KE2FRkegeI8hWEGUUDDpcohq[mm2aX;u M3HXXFI2ODh3OUCy
MCF7  NGG1NY5HfW6ldHnvckBCe3OjeR?= MnPjNk42KML3TR?= Mn\uOFghcA>? Mlu5SG1UVw>? NX:1OmJb\GWlcnXhd4V{KHSqZTDoc41wdG:pb4XzJGRUSiC{ZYDhbZIh\nKncYXlcoNq\XN? M{n0SlI2ODh3OUCy
ACHN M1LLR2NmdGxiVnnhZoltcXS7IFHzd4F6 M4nBUFAvPS1zMDFOwG0> NUHWWphDOC14IHS= MmjESG1UVw>? M4fufYlvcGmkaYTzJJBzd2yrZnXyZZRqd25iaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ? NFTzUIEzPTB4N{e4Oy=>
Caki-2 NWTkR4JGS2WubDDWbYFjcWyrdImgRZN{[Xl? MlvjNE42NTFyIN88US=> MkDZNE03KGR? NGPZVYVFVVOR NEfNPWRqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NUPsTplSOjVyNke3PFc>
A498 NHfOVI9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? NFz5XlMxNjVvMUCg{txO M{XkPVAuPiCm NUn3[nlMTE2VTx?= Mnj6bY5pcWKrdIOgdJJwdGmoZYLheIlwdiCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>? Mn\ENlUxPjd5OEe=
115 M3nJemNmdGxiVnnhZoltcXS7IFHzd4F6 NIDWSGwxNjVvMUCg{txO MWmwMVYh\A>? M{H5VWROW09? MV3pcohq[mm2czDwdo9tcW[ncnH0bY9vKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz M3nWfFI2ODZ5N{i3
117 MlqwR4VtdCCYaXHibYxqfHliQYPzZZk> NYHFcGVjOC53LUGwJO69VQ>? NGj0VGUxNTZiZB?= NVe4O5FjTE2VTx?= NIPkVXZqdmirYnn0d{Bxem:uaX\ldoF1cW:wIHnuJIEh\G:|ZT3k[ZBmdmSnboSgcYFvdmW{ NWjDZmlUOjVyNke3PFc>
ACHN NXXlT2VZTnWwY4Tpc44hSXO|YYm= M{m3XFAvPS9zL{Wg{txO M1i5TVQ5KGh? M2jLd2ROW09? M1jyWYxm[WS|IITvJIlv[3KnYYPl[EBmgHC{ZYPzbY9vKG:oIIC1N{BidmRic3;t[UBxPTNidHHy[4V1KGenbnXzPkBOTE1{LDDhcoQheDJz MX[yOVA3Pzd6Nx?=
Caki-2 NHPqd5hHfW6ldHnvckBCe3OjeR?= MonONE42NzFxNTFOwG0> NGHRZ3o1QCCq MlW3SG1UVw>? MYDs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? M{fsVFI2ODZ5N{i3
A498 NVPxTGl3TnWwY4Tpc44hSXO|YYm= MVmwMlUwOS93IN88US=> M2OxdFQ5KGh? NGXqcndFVVOR MXHs[YFleyC2bzDpcoNz\WG|ZXSg[ZhxemW|c3nvckBw\iCyNUOgZY5lKHOxbXWgdFU{KHSjcnfleEBo\W6nc{qgUWROOixiYX7kJJAzOQ>? MWGyOVA3Pzd6Nx?=
115 MV\GeY5kfGmxbjDBd5NigQ>? Ml[yNE42NzFxNTFOwG0> MYe0PEBp NHfHNItFVVOR Ml\VcIVi\HNidH:gbY5kemWjc3XkJIV5eHKnc4Ppc44hd2ZicEWzJIFv\CC|b33lJJA2OyC2YYLn[ZQh\2WwZYO6JG1FVTJuIHHu[EBxOjF? M2DRNlI2ODZ5N{i3
ACHN NHm3W4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVLWN|FqPSEQvF2= MlHtOFghcA>? NGLke2pFVVOR NXfnV21UcW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MlnWNlUxPjd5OEe=
Caki-2 M2GyU2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkjlOUDPxE1? MUS0PEBp MUHEUXNQ NEPGVIxqdmS3Y3XzJINmdGxiY4njcIUh[XK{ZYP0xsA> NGLp[5czPTB4N{e4Oy=>
A498 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXG1JO69VQ>? NUHYe3c{PDhiaB?= NWS3bHJWTE2VTx?= NYC3UmsycW6mdXPld{Bk\WyuIHP5Z4xmKGG{cnXzeOKh MonNNlUxPjd5OEe=
115 NGr3VI1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mki5OUDPxE1? MV60PEBp M3TUW2ROW09? M37lSolv\HWlZYOgZ4VtdCCleXPs[UBienKnc4VCpC=> M{P1UFI2ODZ5N{i3
ACHN MnvRSpVv[3Srb36gRZN{[Xl? MYi1JO69VQ>? M4DkTVQ5KGh? M3PnbWROW09? MkH5bY5lfWOnczDwOVMu\GWyZX7k[Y51KHOnbnXzZ4Vv[2YEoB?= NFPBcnMzPTB4N{e4Oy=>
Caki-2 MljKSpVv[3Srb36gRZN{[Xl? NVX6UZZbPSEQvF2= M2[4U|Q5KGh? M4PJb2ROW09? MV7pcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi MWSyOVA3Pzd6Nx?=
A498 NVfxT|g3TnWwY4Tpc44hSXO|YYm= NFfvdXY2KM7:TR?= NX3pOHJxPDhiaB?= MVvEUXNQ NITWV49qdmS3Y3XzJJA2Oy2mZYDlcoRmdnRic3Xu[ZNk\W6lZdMg M1HMWlI2ODZ5N{i3
115 NXvjZYp1TnWwY4Tpc44hSXO|YYm= NFPYVWM2KM7:TR?= NWq1UXBGPDhiaB?= NHzPXIZFVVOR MYLpcoR2[2W|IIC1N{1l\XCnbnTlcpQhe2WwZYPj[Y5k\cLi NGrJW5AzPTB4N{e4Oy=>
MOLM-13 NFjaXJFHfW6ldHnvckBCe3OjeR?= MWO2xsDPxE1? NVXQdXRLOC16IHi= NYPTcW03TE2VTx?= MUXpcoNz\WG|ZYOgeIhmKGyndnXsd{Bw\iCyNUOsJG1FVTJuIICyNUBidmRiYXPleJlt[XSnZDDwOVM> MmPKNlQ5QDVyOEK=
MOLM-13 NELwTZZHfW6ldHnvckBCe3OjeR?= MmTVOuKh|ryP NVvPfZB4PiCq M3\0bmROW09? NGHCNpBmdmijbnPld{B1cGViYXPleJlt[XSrb36gc4YhcGm|dH;u[UBJOkJiYX7kJIhm[XRic3jvZ4sheHKxdHXpcpMhUHOyMkegZY5lKEi|cEmw MUGyOFg5PTB6Mh?=
HepG2 NFy4PWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{TLU|czKGh? MlnBSG1UVw>? Mn7OTWM2OD1|NT64OkDDuSB{Lkmg{txO M2DmS|I1QDh2OEC5
HepG2/As MoDLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M3;jflczKGh? M37OSmROW09? NHPDTndKSzVyPU[4MlE{KMLzIEmuOkDPxE1? NG[1e3UzPDh6NEiwPS=>
SMMC7721 M{XORWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIK1epc4OiCq MVvEUXNQ Mn75TWM2OD1|MT6yPEDDuSB2LkKg{txO NULP[3c3OjR6OES4NFk>
SMMC7721/Ac NXm3TWtGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkH5O|IhcA>? NFzCUJRFVVOR MVrJR|UxRTV3LkKxJOKyKDVwMEOg{txO M13hbVI1QDh2OEC5
Huh-7 M{HCOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnO0O|IhcA>? MYHEUXNQ NF3re21KSzVyPUOzMlk3KMLzIEOuPUDPxE1? M2HLUVI1QDh2OEC5
Hep3B MmTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVu3NkBp M2LSS2ROW09? MoC4TWM2OD1{MD6xPEDDuSBzLki0JO69VQ>? NFu1[WUzPDh6NEiwPS=>
HepG2 MUfBdI9xfG:|aYOgRZN{[Xl? MUnpcoR2[2W|IHHwc5B1d3Orcx?= M4GxV|I1QDh2OEC5
SMMC7721 NFj6WmxCeG:ydH;zbZMhSXO|YYm= M2fqNolv\HWlZYOgZZBweHSxc3nz NEfvTnQzPDh6NEiwPS=>
Huh-7 M4\INGFxd3C2b4Ppd{BCe3OjeR?= MWHpcoR2[2W|IHHwc5B1d3Orcx?= MUOyOFg5PDhyOR?=
Hep3B MVjBdI9xfG:|aYOgRZN{[Xl? NH;Zb2NqdmS3Y3XzJIFxd3C2b4Ppdy=> NHTtNmYzPDh6NEiwPS=>
U2OS  Mn3OSpVv[3Srb36gRZN{[Xl? M3X6c|IxKM7:TR?= NW\ncY44OjRiaB?= NWPnbnJ2cW6lcnXhd4V{KHSqZTDtVm5CKGyndnXsd{Bw\sLiQlPMNmEyNCCEQ1zYUOKh[W6mQlPMWy=> MonhNlQ5Pjd{NUm=
AML2 MXPBdI9xfG:|aYOgRZN{[Xl? MnTPNk8yOCEQvF2= Mo\tNlQwPDhiaB?= NXXYcY9PcW6mdXPld{BieG:ydH;zbZM> NF6zbIYzPDZ3OUe0PS=>
MOML13 NGfhSmtCeG:ydH;zbZMhSXO|YYm= NH\2W5ozNzFyIN88US=> NX\XdHlWOjRxNEigbC=> MWrpcoR2[2W|IHHwc5B1d3Orcx?= MUmyOFY2QTd2OR?=
AML2 M3fqS2Z2dmO2aX;uJGF{e2G7 MUOxNO69VQ>? MXKyM|QhcA>? NF7YOY9qdmO{ZXHz[ZMhfGinIHzleoVtKG:oIIC1Ny=> M4TIOVI1PjV7N{S5
AML3 NIXJcpFHfW6ldHnvckBCe3OjeR?= MXOxNO69VQ>? NUHu[3BKOi92IHi= NWLBW4hvcW6lcnXhd4V{KHSqZTDs[ZZmdCCxZjDwOVM> NFi3RpAzPDZ3OUe0PS=>
MOML13 M2[z[2Z2dmO2aX;uJGF{e2G7 MWexNO69VQ>? MoTjNk81KGh? M1Xyd4lv[3KnYYPld{B1cGVibHX2[Ywhd2ZicEWz NHHVblgzPDZ3OUe0PS=>
BeWo NUjIWoVwTnWwY4Tpc44hSXO|YYm= Mni4N|AhyrWP M{PUfVI1KGh? NVLyToNQcW6lcnXhd4V{KHB3MzygUYRuOixicEKxJIFv\CCSdX3hJIF1KHSqZTDwdo91\WmwIHzleoVt Mn;HNlQ1QThzNUS=
BeWo MXjBdI9xfG:|aYOgRZN{[Xl? NWrXXZo6OzBiwsXN M4LKOlI1KGh? NFLh[YNqdmO{ZXHz[ZMh[XCxcITvd4l{ MnHLNlQ1QThzNUS=
OCI NGnFZVhHfW6ldHnvckBCe3OjeR?= NU[0PGRROTBizszN MoHDNlQhcA>? M{XYNJVxemWpdXzheIV{KHSqZTDTU2NUNTFiZYjwdoV{e2mxbh?= Mn3KNlQ1PzN3NkK=
MOLM NF7iO4RHfW6ldHnvckBCe3OjeR?= MkP6NVAh|ryP MmHQNlQhcA>? MlHleZBz\We3bHH0[ZMhfGinIGPPR3MuOSCneIDy[ZN{cW:w M4OwUFI1PDd|NU[y
U2OS  M{DzN2Z2dmO2aX;uJGF{e2G7 MWOyNEDPxE1? NHT0W28zPCCq NXzYT3QzcW6lcnXhd4V{KHSqZTDs[ZZmdHNib3[geIhmKEiRLUGgdJJwfGWrbjDhd{B4\WyuIHHzJJRp\SCyNUOgdJJwfGWrbh?= MWCyOFM3PjByNx?=
RKO MYDGeY5kfGmxbjDBd5NigQ>? MUOyNEDPxE1? NI\xfGkzPCCq M3;ROYlv[3KnYYPld{B1cGVibHX2[Yx{KG:oIITo[UBJVy1zIIDyc5RmcW5iYYOge4VtdCCjczD0bIUheDV|IIDyc5RmcW5? MW[yOFM3PjByNx?=
U2OS  M1PBdGZ2dmO2aX;uJGF{e2G7 MUCyNEDPxE1? MmrzNlQhcA>? MYHpcoR2[2W|IFjPMVEh\XiycnXzd4lwdiCjdDD0bIUhdGW4ZXygc4YhfHKjboPjdolxfGmxbh?= M1Pr[FI1OzZ4MEC3
RKO NVnSboltTnWwY4Tpc44hSXO|YYm= NIX6bnQzOCEQvF2= MVeyOEBp NVrJRmtrcW6mdXPld{BJVy1zIHX4dJJme3Orb36gZZQhfGinIHzleoVtKG:oIITyZY5{[3KrcITpc44> MWeyOFM3PjByNx?=
SMMC-7721  NVT0c4hSS2WubDDWbYFjcWyrdImgRZN{[Xl? NGTQfFkyNjJ3LUKwJO69VQ>? MlvSNlQwPDhxN{KgbC=> NEfZWZZFVVOR Ml3ObY5pcWKrdIOgZ4VtdCCycn;sbYZmemG2aX;uJIRwe2ViYX7kJJRqdWViZHXw[Y5l\W62bIm= MUeyOFI5PjNzMh?=
HuH-7 NHTHNY5E\WyuIG\pZYJqdGm2eTDBd5NigQ>? MnvMNU4zPS1{MDFOwG0> MlXjNlQwPDhxN{KgbC=> MnflSG1UVw>? NInOOIpqdmirYnn0d{Bk\WyuIIDyc4xq\mW{YYTpc44h\G:|ZTDhcoQhfGmvZTDk[ZBmdmSnboTsfS=> MWGyOFI5PjNzMh?=
SMMC-7721  Ml3MRZBweHSxc3nzJGF{e2G7 M1r0NVIxKM7:TR?= NGLNbFQ1QCCq M1zyUGROW09? MkDubY5lfWOnczDhdI9xfG:|aYO= M1fBfVI1Ojh4M{Gy
HuH-7 MoW4RZBweHSxc3nzJGF{e2G7 M1npR|IxKM7:TR?= NX7vOoJEPDhiaB?= NIHmPWxFVVOR NIjBdIZqdmS3Y3XzJIFxd3C2b4Ppdy=> NIKz[G4zPDJ6NkOxNi=>
SMMC-7721  NF;TW3VHfW6ldHnvckBCe3OjeR?= NF;yNZEyOCEQvF2= MUKzOkBp M3vpdWROW09? MUXkc5dvNXKnZ4XsZZRmeyC2aHWgdJJwfGWrbjDlfJBz\XO|aX;uJIxmfmWuIH;mJJBpd3OyaH:tV4VzOzl{LYC1Ny=> Ml7zNlQzQDZ|MUK=
HuH-7 MVLGeY5kfGmxbjDBd5NigQ>? MkjONVAh|ryP M1XEZ|M3KGh? MV\EUXNQ MnfM[I94di2{ZXf1cIF1\XNidHjlJJBzd3SnaX6g[ZhxemW|c3nvckBt\X[nbDDv[kBxcG:|cHjvMXNmejN7Mj3wOVM> MkfPNlQzQDZ|MUK=
AT2 NFr2PHpHfW6ldHnvckBCe3OjeR?= M1rhWVUwOTBizszN M{WyZYxm[WS|IITvJIEhe3Wkc4ThcpRq[WxiYXPjeY12dGG2aX;uJI9nKHSqZTDwOVMheHKxdHXpckBieyC5ZXzsJIF{KHSqZTDlfJBz\XO|aX;uJI9nKGm2czDkbZJm[3RidHHy[4V1eyCyMkGsJG1FVTJiYX7kJJRp\SCycn:tZZBweHSxdHnjJGJCYCCjbnSgVHVOSSCycn;0[Ylve8Li NX7vZotZOjR{NECyNFM>
REH Mn64SpVv[3Srb36gRZN{[Xl? MYK1M|ExKM7:TR?= MoTQcIVi\HNidH:gZUB{fWK|dHHueIlidCCjY3P1cZVt[XSrb36gc4YhfGinIIC1N{Bxem:2ZXnuJIF{KHenbHygZZMhfGinIHX4dJJme3Orb36gc4YhcXS|IHTpdoVkfCC2YYLn[ZR{KHB{MTygUWROOiCjbnSgeIhmKHC{bz3hdI9xfG:2aXOgRmFZKGGwZDDQWW1CKHC{b4TlbY5{yqB? NH61b2kzPDJ2MEKwNy=>
UoCB6 M1zDPGZ2dmO2aX;uJGF{e2G7 NGjxUGM2NzFyIN88US=> NGq5eVRt\WGmczD0c{BiKHO3YoP0ZY51cWGuIHHjZ5VufWyjdHnvckBw\iC2aHWgdFU{KHC{b4TlbY4h[XNid3XscEBieyC2aHWg[ZhxemW|c3nvckBw\iCrdIOg[Ilz\WO2IIThdodmfHNicEKxMEBOTE1{IHHu[EB1cGVicILvMYFxd3C2b4TpZ{BDSVhiYX7kJHBWVUFicILveIVqdnQEoB?= MUmyOFI1ODJyMx?=
AT2 M1LQW2NmdGxiVnnhZoltcXS7IFHzd4F6 NYrpV|V5OC1{NTFOwG0> NFjDOXBqdmirYnn0d{Bk\WyuII\pZYJqdGm2eTDkc5NmKGSncHXu[IVvfGy7 NVHhN2k3OjR{NECyNFM>
REH MmGzR4VtdCCYaXHibYxqfHliQYPzZZk> M3m3eVAuOjVizszN M2\iO4lvcGmkaYTzJINmdGxidnnhZoltcXS7IHTvd4Uh\GWyZX7k[Y51dHl? NFjVe2MzPDJ2MEKwNy=>
UoCB6 NYG3VnpDS2WubDDWbYFjcWyrdImgRZN{[Xl? MUGwMVI2KM7:TR?= MVrpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCmb4PlJIRmeGWwZHXueIx6 NITVfZczPDJ2MEKwNy=>
A2780 NIT2bWRHfW6ldHnvckBCe3OjeR?= NI\TZlk2NzFyL{KwJO69VQ>? NUXETZRVOjRiaB?= MXH1dJJm\3WuYYTld{BxPTNuIF3EUVItKHB{MTDhcoQhTFJ3IIDyc5RmcW5ibHX2[Yx{KGSxc3Wg[IVx\W6mZX70cJnDqA>? NVzYe3dHOjRzM{[xOFc>
H460 NF3KfXZHfW6ldHnvckBCe3OjeR?= NGHtNo82NzFyL{KwJO69VQ>? NWLi[Fh2OjRiaB?= M4PkSJVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi NH:2[28zPDF|NkG0Oy=>
Lovo  Ml60SpVv[3Srb36gRZN{[Xl? NF\3dFM2NzFyL{KwJO69VQ>? NVT3XGNTOjRiaB?= M{nCVZVxemWpdXzheIV{KHB3MzygUWROOixicEKxJIFv\CCGUkWgdJJwfGWrbjDs[ZZmdHNiZH;z[UBl\XCnbnTlcpRtgcLi MVGyOFE{PjF2Nx?=
A2780 NFnRN2VCeG:ydH;zbZMhSXO|YYm= NIKyPGY2NzFyL{KwJO69VQ>? MVeyOEBp NV7CN|Z1\W6qYX7j[ZMh[XCxcITvd4l{KGmwZIXjeIlwdiCkeTDENlY6UC:HMUm1VkBwfmW{IILoWHJCUUx? MUSyOFE{PjF2Nx?=
H460 NVnoXFl5SXCxcITvd4l{KEG|c3H5 M1G5XVUwOTBxMkCg{txO MYCyOEBp NGXxSWhmdmijbnPld{BieG:ydH;zbZMhcW6mdXP0bY9vKGK7IFSyOllJN0VzOUXSJI93\XJicnjUVmFKVA>? M4G5OVI1OTN4MUS3
Lovo  MojyRZBweHSxc3nzJGF{e2G7 M2TOXVUwOTBxMkCg{txO NGjSbXozPCCq MYPlcohidmOnczDhdI9xfG:|aYOgbY5lfWO2aX;uJIJ6KER{NknIM2UyQTWUIH;2[ZIhemiWUlHJUC=> MY[yOFE{PjF2Nx?=

多くの細胞株試験データを見る場合、クリックしてください

体内試験 Oral administration of Nutlin-3 at 200 mg/kg twice daily for 3 weeks significantly inhibits the tumor growth of SJAS-1 xenografts by 90%, comparable with the effect of doxorubicin treatment with 81% inhibition of tumor growth. [1]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[1]

+ 展開

Biacore study:

Competition assay is performed on a Biacore S51. A Series S Sensor chip CM5 is utilized for the immobilization of a PentaHis antibody for capture of the His-tagged p53. The level of capture is ~200 response units (1 response unit corresponds to 1 pg of protein per mm2). The concentration of MDM2 protein is kept constant at 300 nM. Nutlin-3 is dissolved in DMSO at 10 mM and further diluted to make a concentration series of Nutlin-3 in each MDM2 test sample. The assay is run at 25 °C in running buffer (10 mM Hepes, 0.15 M NaCl, 2% DMSO). MDM2-p53 binding in the presence of Nutlin-3 is calculated as a percentage of binding in the absence of Nutlin-3 and IC50 is calculate
細胞試験:

[1]

+ 展開
  • 細胞株: HCT116, RKO, SJSA-1, SW480, and MDA-MB-435
  • 濃度: Dissolved in DMSO, final concentrations ~ 30 μM
  • 反応時間: 8, 24, and 48 hours
  • 実験の流れ:

    Cells are exposed to various concentrations of Nutlin-3 for 8, 24 and 48 hours. The transcriptional levels of p21 and MDM2 genes are analyzed by real-time PCR, and protein levels by western blotting. Cell viability is measured by the MTT assay. Cell apoptosis is determined by terminal deoxynucleotidyl transferase-mediated deoxyuridine triphosphate nick end labeling (TUNEL) staining with flow cytometry and fluorescence microscopy.


    (参考用のみ)
動物試験:

[1]

+ 展開
  • 動物モデル: Athymic female nude mice (Nu/Nu-nuBR) injected subcutaneously with SJSA-1 cells
  • 製剤: Formulated in 2% Klucel, 0.5% Tween 80
  • 投薬量: 200 mg/kg
  • 投与方法: Orally, twice a day
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 100 mg/mL (171.96 mM)
Ethanol 30 mg/mL (51.59 mM)
Water Insoluble

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 581.5
化学式

C30H30Cl2N4O4

CAS No. 890090-75-2
保管
別名 N/A

便利ツール

モル濃度計算器

モル濃度計算器

解決のために必要とされるマス、ボリュームまたは濃度を計算してください。

マス (g) = 濃度 (mol/L) x ボリューム (L) x 分子量 (g/mol)

モル濃度計算器方程式

  • マス
    濃度
    ボリューム
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備することを要求される希釈剤を計算してください. セレック希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 輸入 輸出 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

マス 濃度 ボリューム 分子量

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    Is this a racemic mixture of Nutlin-3a and Nutlin-3b or just the Nutlin-3a enantiomer?

  • 回答:

    It is a racemate.

Mdm2シグナル伝達経路

相関Mdm2製品

Tags: Nutlin-3を買う | Nutlin-3 ic50 | Nutlin-3供給者 | Nutlin-3を購入する | Nutlin-3費用 | Nutlin-3生産者 | オーダーNutlin-3 | Nutlin-3化学構造 | Nutlin-3分子量 | Nutlin-3代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID